80 Chapter 4 27. Ford T, Stanley B, Good R, Rocchiccioli P, Mc Entegart M, Watkins S, et al. Cor mic A: a randomized controlled trial of coronary function testing in angina and no obstructive coronary disease. QJM. (2019) 112(9):725–6. doi: 10.1016/j. jacc.2018.09.006 28. Fournier JA, Cortacero JA, Tura A, Hernandez-Aparicio C, Granado C, Vallejo J. Effects of intracoronary injection of ergonovine on angiographic normal coronary arteries: study of 108 consecutive patients. Clin Cardiol. (1989) 12(10):561–8. doi: 10.1002/clc.4960121003 29. Nishimiya K, Suda A, Fukui K, Hao K, Takahashi J, Matsumoto Y, et al. Prognostic links between OCT-delineated coronary morphologies and coronary functional abnormalities in patients with INOCA. JACC Cardiovasc Interv. (2021) 14(6):606–18. doi: 10.1016/j.jcin.2020.12.025 30. Sato K, Kaikita K, Nakayama N, Horio E, Yoshimura H, Ono T, et al. Coronary vasomotor response to intracoronary acetylcholine injection, clinical features, and long-term prognosis in 873 consecutive patients with coronary spasm: analysis of a single-center study over 20 years. J Am Heart Assoc. (2013) 2(4):e000227. doi: 10.1161/JAHA.113.000227 31. Sueda S, Miyoshi T, Sasaki Y, Sakaue T, Habara H, Kohno H. One of six patients with non-ischemic heart disease exhibit provoked coronary spasms: non-ischemic heart disease associated with ischemia? Intern Med. (2015) 54(3):281–6. doi: 10.2169/internalmedicine.54.2660 32. Sugiishi M, Takatsu F. Cigarette-smoking is a major risk factor for coronary spasm. Circulation. (1993) 87(1):76–9. doi: 10.1161/01.CIR.87.1.76 33. Sueda S, Kohno H, Miyoshi T, Sakaue T, Sasaki Y, Habara H. Maximal acetylcholine dose of 200 mug into the left coronary artery as a spasm provocation test: comparison with 100 mug of acetylcholine. Heart Vessels. (2015) 30(6):771–8. doi: 10.1007/s00380-014-0563-y 34. Ong P, Athanasiadis A, Borgulya G, Vokshi I, Bastiaenen R, Kubik S, et al. Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation. (2014) 129(17):1723–30. doi: 10.1161/CIRCULATIONAHA.113.004096 35. Mileva N, Nagumo S, Mizukami T, Sonck J, Berry C, Gallinoro E, et al. Prevalence of coronary microvascular disease and coronary vasospasm in patients with nonobstructive coronary artery disease: systematic review and meta-analysis. J Am Heart Assoc. (2022) 11(7):e023207. doi: 10.1161/JAHA.121.023207 36. Beltrame JF, Sasayama S, Maseri A. Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. J Am Coll Cardiol. (1999) 33(6):1442–52. doi: 10.1016/S0735-1097(99)00073-X 37. Ong P, Athanasiadis A, Borgulya G, Mahrholdt H, Kaski JC, Sechtem U. High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA study (abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol. (2012) 59(7):655–62. doi: 10.1016/j.jacc.2011.11.015 38. Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas A, et al. An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European society of cardiology working group on coronary pathophysiology & microcirculation endorsed by coronary vasomotor disorders international study group. EuroIntervention. (2021) 16(13):1049–69. doi: 10.4244/ EIJY20M07_01
RkJQdWJsaXNoZXIy MTk4NDMw